Journal
CANCER LETTERS
Volume 354, Issue 1, Pages 21-27Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2014.08.013
Keywords
Mesenchymal uterine tumors; Endometrial stromal sarcomas; Chemotherapy; Histone deacetylase inhibitors; Vorinostat
Categories
Funding
- Lore Saldow Research Fund
Ask authors/readers for more resources
Endometrial stromal sarcoma (ESS) and undifferentiated endometrial sarcoma (UES) are very rare gynecologic malignancies. Due to the rarity and heterogeneity of these tumors, little is known about their epidemiology, pathogenesis, and molecular pathology. Our previous studies have described deregulation of histone deacetylases expression in ESS/UES samples. Some of these enzymes can be inhibited by substances which are already approved for treatment of cutaneous T-cell lymphoma. On the basis of published data, they may also provide a therapeutic option for ESS/UES patients. Our review focuses on molecular mechanisms of ESS/UES. It describes various aspects with special emphasis on alteration of histone deacetylation and its possible relevance for novel therapies. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available